How much does a box of Nintedanib cost? Is it cost-effective?

Nintedanib (Nintedanib), as the original research drug for idiopathic pulmonary fibrosis and other fibrotic lung diseases, has been officially launched in China and is included in Class B medical insurance, but it is only reimbursed for patients who meet the indications. Common packaging specifications are 100mg 30 capsules and 150mg 30 capsules. The market price per box is about 4,000 yuan. For patients not covered by medical insurance, they need to pay for it at their own expense. Considering that pulmonary fibrosis is a chronic and progressive disease, the cost of long-term medication is relatively high, but its clinical value in delaying disease progression and reducing acute exacerbations makes nintedanib still highly cost-effective between efficacy and price.

In the international market, the price of nintedanib varies by region. The Turkish and Indian versions of nintedanib are mostly available in specifications of 100 mg 60 tablets and 150 mg 60 tablets. The price is usually between more than 4,000 to 5,000 yuan, which fluctuates due to exchange rates and import costs. At the same time, some developing countries, such as Laos, Bangladesh and India, also produce generic versions. The active ingredients are similar to the original drugs, and the price is significantly reduced, about more than 600 yuan per box. This provides patients with limited financial resources with a more accessible option, significantly reducing the burden of long-term treatment.

The cost-effectiveness of nintedanib is not only reflected in the price of the drug, but also in its clinical efficacy and quality of life improvement. By delaying the decline in lung function, reducing exacerbations, and improving ability to carry out daily activities, patients can achieve substantial health gains during long-term treatment. Especially in pulmonary fibrosis, a chronic disease that cannot be cured, the rational use of nintedanib combined with life management and rehabilitation training can significantly improve the overall value of treatment.

Generally speaking, nintedanib is available through various channels in domestic and foreign markets. The price of the original drug is relatively high, but it has outstanding performance in terms of efficacy, sustainability and improvement of quality of life. The emergence of generic drugs has further improved accessibility and reduced the financial pressure on patients, making it the drug of choice for long-term management of patients with pulmonary fibrosis.

Reference materials:https://en.wikipedia.org/wiki/Nintedanib